Quotient Sciences Acquires CDMO Arcinova
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.
Quotient Sciences, a UK-based drug development and manufacturing accelerator, announced on Feb. 9, 2021 that it has acquired Arcinova, a UK-based multiservice contract development and manufacturing organization. The acquisition expands Quotient’s service portfolio and will enable the integration of drug substance, drug product, and clinical testing capabilities under one organization.
The integration of capabilities is expected to further simply and accelerate outsourced development programs, the company stated in a press release. Under the deal, Arcinova’s minority equity partner, BGF, will exit the business.
“I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch,” said Mark Egerton, PhD, CEO of Quotient Sciences, in the company press release. “I’d also like to take this moment to thank our private equity partner, Permira, for supporting our ambitious growth plans.”
“Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility, and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers,” said Professor Ian Shott, co-founder and executive chairman of Arcinova, in the press release.
Source: Quotient Sciences
